Meissa also announced TODAY interim results from the first-in-human study of MV-012-968, the company's LAV candidate for respiratory syncytial virus, showing MV-012-968 generates an immune response in healthy adults.
These initial clinical data support the further development of MV-012-968 for RSV and the application of Meissa's technology to a COVID-19 vaccine candidate.
Meissa's COVID-19 vaccine candidate, MV-014-210, was developed on the company's codon deoptimized RSV vaccine platform with the goal of creating safe, potent, stable, and cost-effective intranasal vaccines.
The company's platform technology can potentially solve challenging obstacles in modern vaccinology such as suboptimal immune responses, vaccine stability, and manufacturing.
Meissa's COVID-19 vaccine candidate, MV-014-210, was derived by modifying the company's RSV LAV candidate, MV-012-968, replacing the RSV glycoproteins with a functioning SARS-CoV-2 Spike protein.
Meissa's COVID-19 vaccine candidate offers significant potential advantages for global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce systemic and mucosal immunity, and a straightforward, economical, and scalable manufacturing process capable of supplying global demands. Clinical trials are expected to begin in early 2021.
In animal models evaluated previously, Meissa's RSV LAV candidate MV-012-968 induced a strong mucosal IgA response and a serum-neutralizing antibody response against RSV.
MV-012-968 has been safe and well-tolerated among healthy RSV sero-low adults assessed through day 56 in an ongoing randomised, open-label, dose-ranging Phase 1a trial (ClinicalTrials.gov Identifier NCT04227210).
A 106 PFU dose of MV-012-968 resulted in no detectable shed vaccine virus nasally, indicating heavy attenuation, and yet induced RSV-specific mucosal IgA in the majority of vaccine recipients, despite pre-existing immunity to RSV.
Meissa is a private biotechnology company focused on the advancement of vaccines for respiratory viruses. Meissa was founded on proprietary technologies employing reverse genetics for rational design of more effective live attenuated vaccines.
The technology is exclusively licensed from Emory University and Children's Healthcare of Atlanta. Dr. Moore, together with Dr. Roderick Tang, a vaccine biotech expert, cofounded Meissa.
Meissa is currently a resident company at Johnson and Johnson Innovation JLABS in South San Francisco.
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study